[11] Shiba, K., Tsuchiya, K., Komiya, C., et al.(2018). Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH, Sci Rep 8, 2362. https://doi.org/10.1038/s41598-018-19658-7 [12] Zhou J, Zhu J, Yu S J, et ...
目前,已上市的降糖药种类繁多,其中,钠-葡萄糖协同转运蛋白2抑制剂(sodium-dependent glucose transporters 2 inhibitor,SGLT-2)作为新型口服降糖药物,可以抑制肾脏对葡萄糖的重吸收,使过量的葡萄糖从尿液中排出,降低血糖,在全球各大指南中的地位逐年攀升。 已上市的SGLT-2抑制剂...
[3]Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney...
近日，一篇发表在国际杂志Neurology上题为“SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes”的研究报告中，来自延世大学医学院等机构的科学家们发现，一类糖尿病药物或能降低痴呆症和帕金森疾病的风险。什么是SGLT2抑制剂？SGLT2抑制剂，也被称为格列净类（glif...
新型口服降糖药(OAD)钠-葡萄糖共转运蛋白2抑制剂(SGLT2i,sodium-glucose cotransporter 2 inhibitor)是一类新型口服降糖药物,其主要作用机制是通过抑制肾脏近端小管中的钠-葡萄糖协同转运蛋白2(SGLT2),从而减少对葡萄糖的重吸收,增加尿糖排泄,降低血糖水平。这种机制不依赖于胰岛素的分泌或增加胰岛素的灵敏度。
[11]. Vallon V, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. American Journal of Physiology-Renal Physiology, 2014. 306(2): p. F194-F204. ...
1. Giugliano D, Longo M, Caruso P, et al. Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial [published online ahead of print, ...
Niessen SJM, Voth R, Kroh C, Hennings L. Once daily oral therapy for feline diabetes mellitus: SGLT-2-inhibitor velagliflozin as standalone therapy compared to insulin injection therapy in diabetic cats. Abstract presented at: 32nd ECVIM-CA Congress; September 1-3, 2022; Göteborg, Swede...
[10]Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Lancet, 2022, 400(10365): 1788-1801. [11]Zinman B, et al. N Engl J Med, 2015, 373(22): 2117-2128. ...
[11] Shiba, K., Tsuchiya, K., Komiya, C., et al.(2018). Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH, Sci Rep 8, 2362.https://doi.org/10.1038/s41598-018-19658-7 ...